Posters & Publications

Spinogenix publishes reports and posters of our research which you can view below.

Rapid and Durable Improvements in Cognitive and Neurophysiological Outcomes in mild-to-moderate AD patients treated with the synaptic regenerative drug, Tazbentetol

Publication: AAIC
Date: 2026

SPG601-associated modulation of resting-state EEG and improvement in executive function in a fragile X syndrome randomized controlled crossover study

Publication: Scientific Reports
Date: 2026

SPG302 mitigates diabetic retinal neuropathy and inner retinal damage in a genetic mouse model of diabetes

Publication: Experimental Eye Research
Date: 2026

Phase 2a Topline Clinical Results Evaluating Neurophysiological and Functional Measures in SPG302-treated ALS Participants

Publication: NEALS
Date: 2025

Early positive signals of cognitive outcomes in mild to moderate Alzheimer patients treated with the synaptic regenerative small molecule, SPG302

Publication: AAIC
Date: 2025

SPG302 protects retinal ganglion cells and preserves visual function by preserving synaptic activity in a mouse model of glaucoma

Publication: Experimental Eye Research
Date: 2025

Novel Regenerative Drug, SPG302 Promotes Functional Recovery of Diaphragm Muscle Activity After Cervical Spinal Cord Injury

Publication: The Journal of Physiology
Date: 2023

SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease

Publication: Neurotherapeutics
Date: 2021